We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?
Read MoreHide Full Article
Key Takeaways
Penumbra received CE Mark in Europe for THUNDERBOLT after recent FDA approval in the US.
Penumbra's international revenues rose 16.5% in Q1 2026 and made up 20.9% of total revenues.
Penumbra reported 90-day STORM-PE data showing improved function with CAVT plus anticoagulation.
Penumbra, Inc. (PEN - Free Report) recently received CE Mark in Europe for THUNDERBOLT, following the FDA approval in the United States last week. THUNDERBOLT is a computer-assisted vacuum thrombectomy (CAVT) technology, designed to address acute ischemic stroke globally.
The introduction of this technology in Europe is a significant milestone in Penumbra’s ongoing plan of advancing stroke care tools globally.
Likely Trend of PEN Stock Following the News
After the announcement, PEN shares edged down marginally by 0.2%, closing at $318.21 on Monday.
Penumbra continues to build its presence outside the United States in key developed markets. In the first quarter of 2026, international revenues rose 16.5% year over year and represented 20.9% of total revenues.
Over time, broader access to the company’s thrombectomy platform can diversify the revenue base. International sales also provide an avenue to expand utilization of newer platforms as regulatory clearances and commercial resources scale. Henceforth, we expect the latest CE approval to boost a positive market sentiment toward PEN stock in the upcoming days.
Presently, Penumbra boasts a market capitalization of $12.44 billion. The Zacks Consensus Estimate for 2026 earnings suggests a 32.3% year-over-year increase and the same for revenues implies 13.3% growth. The company beat on earnings in three of the trailing four quarters and missed in one.
About PEN’s THUNDERBOLT
Powered by the Penumbra ENGINE, THUNDERBOLT introduces modulated aspiration to Penumbra’s neuro thrombectomy portfolio, offering advanced CAVT technology designed to detect, fatigue and completely ingest clot at the site of the occlusion. THUNDERBOLT has the potential to shorten procedure times by improving patient safety, delivering better outcomes and streamlining care for the physicians who treat them.
THUNDERBOLT will be pre-packaged with one of the company’s market-leading catheters – RED 62, RED 68, RED 72 SILVER LABEL with SENDit technology.
Importance of the THUNDERBOLT Expansion in Europe
Stroke is the second leading cause of death worldwide and if a blood clot is not fully removed, there is an increased risk of serious complications, disability or death. A recent analysis by The Lancet Neurology stated that stroke mortality worldwide is projected to increase 50% between 2020 and 2050. Penumbra’s THUNDERBOLT represents a first-of-its-kind advancement in acute ischemic stroke care, being the only CAVT device available for stroke treatment in Europe and the United States.
Image Source: Zacks Investment Research
Another Recent Development by PEN
Penumbra unveiled 90-day favorable results of the STORM-PE randomized controlled trial. The trial found that patients with acute intermediate-high risk pulmonary embolism who were treated with CAVT plus anticoagulation achieved greater functional improvement and a higher proportion of patients achieving NYHA Class I compared to anticoagulation alone.
PEN Stock Price Performance
Over the past year, PEN’s shares have gained 23.1% against the industry’s 2.1% decline.
PEN’s Zacks Rank and Key Picks
Penumbra currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Integra LifeSciences (IART - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Globus Medical has an earnings yield of 5.5%, well ahead of the industry’s negative 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.3%. The company’s shares have rallied 43.8% against the industry’s 4.8% decline over the past year.
Integra LifeSciences, carrying a Zacks Rank #2 at present, has an earnings yield of 16% against the industry’s negative 3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.
View the Zacks #1 Rank List
Image: Bigstock
Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?
Key Takeaways
Penumbra, Inc. (PEN - Free Report) recently received CE Mark in Europe for THUNDERBOLT, following the FDA approval in the United States last week. THUNDERBOLT is a computer-assisted vacuum thrombectomy (CAVT) technology, designed to address acute ischemic stroke globally.
The introduction of this technology in Europe is a significant milestone in Penumbra’s ongoing plan of advancing stroke care tools globally.
Likely Trend of PEN Stock Following the News
After the announcement, PEN shares edged down marginally by 0.2%, closing at $318.21 on Monday.
Penumbra continues to build its presence outside the United States in key developed markets. In the first quarter of 2026, international revenues rose 16.5% year over year and represented 20.9% of total revenues.
Over time, broader access to the company’s thrombectomy platform can diversify the revenue base. International sales also provide an avenue to expand utilization of newer platforms as regulatory clearances and commercial resources scale. Henceforth, we expect the latest CE approval to boost a positive market sentiment toward PEN stock in the upcoming days.
Presently, Penumbra boasts a market capitalization of $12.44 billion. The Zacks Consensus Estimate for 2026 earnings suggests a 32.3% year-over-year increase and the same for revenues implies 13.3% growth. The company beat on earnings in three of the trailing four quarters and missed in one.
About PEN’s THUNDERBOLT
Powered by the Penumbra ENGINE, THUNDERBOLT introduces modulated aspiration to Penumbra’s neuro thrombectomy portfolio, offering advanced CAVT technology designed to detect, fatigue and completely ingest clot at the site of the occlusion. THUNDERBOLT has the potential to shorten procedure times by improving patient safety, delivering better outcomes and streamlining care for the physicians who treat them.
THUNDERBOLT will be pre-packaged with one of the company’s market-leading catheters – RED 62, RED 68, RED 72 SILVER LABEL with SENDit technology.
Importance of the THUNDERBOLT Expansion in Europe
Stroke is the second leading cause of death worldwide and if a blood clot is not fully removed, there is an increased risk of serious complications, disability or death. A recent analysis by The Lancet Neurology stated that stroke mortality worldwide is projected to increase 50% between 2020 and 2050. Penumbra’s THUNDERBOLT represents a first-of-its-kind advancement in acute ischemic stroke care, being the only CAVT device available for stroke treatment in Europe and the United States.
Image Source: Zacks Investment Research
Another Recent Development by PEN
Penumbra unveiled 90-day favorable results of the STORM-PE randomized controlled trial. The trial found that patients with acute intermediate-high risk pulmonary embolism who were treated with CAVT plus anticoagulation achieved greater functional improvement and a higher proportion of patients achieving NYHA Class I compared to anticoagulation alone.
PEN Stock Price Performance
Over the past year, PEN’s shares have gained 23.1% against the industry’s 2.1% decline.
PEN’s Zacks Rank and Key Picks
Penumbra currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Integra LifeSciences (IART - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Globus Medical has an earnings yield of 5.5%, well ahead of the industry’s negative 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.3%. The company’s shares have rallied 43.8% against the industry’s 4.8% decline over the past year.
GMED carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Integra LifeSciences, carrying a Zacks Rank #2 at present, has an earnings yield of 16% against the industry’s negative 3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.